Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

12.83USD
26 May 2017
Change (% chg)

$0.04 (+0.31%)
Prev Close
$12.79
Open
$12.77
Day's High
$13.02
Day's Low
$12.62
Volume
1,434,429
Avg. Vol
3,595,709
52-wk High
$32.74
52-wk Low
$8.32

Latest Key Developments (Source: Significant Developments)

EyeGate receives milestone payment from Valeant
Monday, 22 May 2017 07:30am EDT 

May 22 (Reuters) - Eyegate Pharmaceuticals Inc : :EyeGate receives milestone payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients.EyeGate Pharmaceuticals Inc - granted Valeant exclusive, worldwide commercial and manufacturing rights to co's EyeGate II delivery system and EGP-437 combination product.EyeGate Pharmaceuticals - co is eligible to receive developmental and sales-based milestones totaling up to about $99.0 million, royalties on valeant's net sales of product.  Full Article

Glycyx Pharmaventures and Valeant agree to terms of licensing agreement in oncology
Wednesday, 15 Mar 2017 01:07pm EDT 

Glycyx Pharmaventures : Glycyx Pharmaventures and Valeant Pharmaceuticals agree to binding terms of licensing agreement in the field of oncology . Deal allows co to commercialize products containing Methylnaltrexone Bromide for oncology indications in countries outside US, Canada .Glycyx would pay sales-based milestones and royalties to Valeant.  Full Article

U.S. FDA approves siliq to treat adults with moderate-to-severe plaque psoriasis
Wednesday, 15 Feb 2017 06:16pm EST 

Valeant Pharmaceuticals International Inc : U.S. FDA approves siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis . U.S. FDA - siliq is marketed by Bridgewater, New Jersey-based Valeant Pharmaceuticals . U.S. FDA - "suicidal ideation and behavior, including completed suicides, have occurred in patients treated with siliq during clinical trials" . U.S. FDA - because of the observed risk of suicidal ideation and behavior, the labeling for siliq includes a boxed warning .FDA - because of observed risk of suicidal ideation, siliq is only available through restricted program under risk evaluation and mitigation strategy.  Full Article

FDA approves new psoriasis drug
Wednesday, 15 Feb 2017 05:56pm EST 

Valeant Pharmaceuticals International Inc :FDA approves new psoriasis drug.  Full Article

Pershing Square Capital Management raises sole share stake in Chipotle
Tuesday, 14 Feb 2017 04:30pm EST 

Pershing Square Capital Management LP: Pershing Square Capital Management LP raises sole share stake in Chipotle Mexican Grill Inc to 2.9 million shares from 554,213 shares . Pershing Square Capital Management LP cuts sole share stake in Valeant Pharma by 16.1 percent to 18.11 million shares - SEC filing .Pershing square capital management - change in holdings are as of Dec 31, 2016 and compared with the previous quarter ended as of Sept 30, 2016.  Full Article

Valeant appoints William Humphries as EVP, Dermatology
Monday, 12 Dec 2016 04:05pm EST 

Valeant Pharmaceuticals International Inc : Valeant Pharmaceuticals International Inc - Ari Kellen, Robert Rosiello and Anne Whitaker to leave company .Valeant appoints William D. Humphries as EVP, Dermatology.  Full Article

Valeant announces price changes for neurology, GI, urology portfolis
Friday, 14 Oct 2016 12:51pm EDT 

Valeant Pharmaceuticals International Inc : Valeant Patient Access and Pricing Committee comments on recent pricing action decisions . Patient Access and Pricing Committee has made decisions regarding price changes of products in company's neurology, GI and urology portfolios . Planned wholesale acquisition price changes, effective October 14, range from 2.0 percent to 9.0 percent . There will be no pricing adjustments this year on dermatology and ophthalmology products .2016 pricing actions across its U.S. branded RX portfolio, represent an increase of less than 2.0 percent within calendar 2016 year.  Full Article

Pharming Group 8-month product sales rise to 6.2 million euros
Monday, 3 Oct 2016 01:00am EDT 

Pharming Group Nv : 8-month product sales 6.2 million euros ($6.97 million)versus 5.6 million euros year ago . 8-month operating loss 8.3 million euros versus loss of 8.1 million euros year ago . Expect that both sales and gross profits will continue to improve during remainder of year and that investments in research and development will continue to increase gradually. .Would expect to become profitable at operating level during 2017.  Full Article

Valeant acquires Canadian rights for Contrave in treatment of obesity
Tuesday, 30 Aug 2016 08:00am EDT 

Valeant Pharmaceuticals International Inc : Valeant acquires the Canadian rights for Contrave® in the treatment of obesity . Valeant expects to file with health Canada for regulatory approval by January 2017 . Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activities and expenses . Says Orexigen and Valeant anticipate launching Mysimba in 11 countries in Q4 of 2016 .Orexigen and Valeant anticipate launching Mysimba in 2 countries, in addition to 11 countries, in Q1 of 2017.  Full Article

Valeant enters into amendment, restates credit and guaranty agreement
Tuesday, 23 Aug 2016 05:45pm EDT 

Valeant Pharmaceuticals International Inc : On August 23 entered into an amendment to its third amended and restated credit and guaranty agreement, dated as of February 13, 2012 . Amendment reduces minimum interest coverage maintenance covenant to 2.00 to 1.00 for quarters ending on or after Sept. 30, 2016 . Amendment permits issuance of secured notes with shorter maturities and incurrence of other indebtedness, in each case to repay term loans under credit agreement . Amendment no. 13 also increases each of applicable interest rate margins under credit agreement by 0.50 percent Source: (http://bit.ly/2by7pB5) Further company coverage: [VRX.TO] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

More From Around the Web

BRIEF-EyeGate receives milestone payment from Valeant

* EyeGate receives milestone payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients